for people ages 14-30 (full criteria)
at San Francisco, California
study started
estimated completion:
Danielle A Schlosser



This project will result in the development of a personalized intervention strategy to improve motivation for treatment engagement and functional outcomes in individuals with a recent onset of schizophrenia. Motivational impairment is arguably the single most important factor that determines a patient's ability to engage in and adhere to effective treatment. In our study, sixty participants will be enrolled in a randomized controlled trial comparing the feasibility and tolerability of two types of motivational interventions (Daily Goals or PRIME), and a neuroplasticity-based cognitive training program. Participants are randomized to either receive Daily Goals or PRIME for 8 weeks, after which, both conditions will also receive an 8-week course of cognitive training delivered via iPads. Participants will undergo pre/post-testing and a 6-month follow-up to determine feasibility and efficacy of the interventions. By enhancing motivation, schizophrenia patients would be able to engage more fully with treatment and develop full and productive lives. This study may also pave the way forward for other health conditions in which motivational impairments impede health outcomes. All assessments will be conducted at the University of California, San Francisco; however, we offer some assessments to be done remotely.

Official Title

Developing an Intervention Strategy to Enhance Motivation in Recent Onset Schizophrenia


Schizophrenia PRIME Cognitive Training PRIME + CT


You can join if…

Open to people ages 14-30

  • Diagnosis of schizophrenia, schizoaffective, or schizophreniform disorder.
  • Onset of diagnosis within 5 years.
  • 14-30 years old.
  • Clinically stable (outpatient status for 1 month and stable dose of medication for 1 month).
  • Good general health

You CAN'T join if...

  • Substance dependence within the past 12 months,
  • Current substance abuse,
  • No history of neurological disorder


  • University of California San Francisco
    San Francisco California 94143 United States


in progress, not accepting new patients
Start Date
Completion Date
University of California, San Francisco
Lab website
Lead Scientist
Danielle A Schlosser
Study Type
Last Updated
November 2016